Magyar Telekom Select Mavenir’s Converged Packet Core
17.11.2022 10:00:00 EET | Business Wire | Press release
Mavenir, the Network Software Provider building the future of networks with cloud-native software that runs on any cloud and transforms the way the world connects, announce the selection by Magyar Telekom, the leading Hungarian telecommunications service provider, and a subsidiary of Deutsche Telekom, to deploy a cloud-native containerized Converged Packet Core.
Magyar Telekom will use Deutsche Telekom’s locally deployed private cloud solution. Mavenir’s containerized converged packet core will lay the foundation for quickly and easily deploying new enterprise applications and services, taking advantage of 5G features such as low latency and network slicing.
Laszlo Boka, Platform and Core Services Tribe Lead at Magyar Telekom said: “It was important for us to partner with a software provider that could deliver on three main fronts: a Converged Packet Core to support all access technology integration from 2G to 5G, an open architecture that could run on our specified hardware and software platforms, and seamless integration with third-party network functions. Mavenir is a great candidate for us to provide on all three fronts, and we look forward to what the future will bring.”
Mavenir’s 5G Core solution is part of its cloud-native MAVcore portfolio based on an open architecture that offers easy scaling of applications and services, hardware decoupling, agility, portability, and cloud-native resilience.
Key attributes include:
- Open Architecture : uses Deutsche Telekom-defined hardware and a Kubernetes-based platform.
- Network slicing with dedicated control and user plane network functions for meeting strict service level agreements.
- Cloud-native design : a fully containerized solution based on stateless microservice architecture that allows better resiliency and faster recovery in the event of network failures. It also enables the easy onboarding of users on Deutsche Telekom Containers-as-a-Service (CaaS).
- Third-party vendor network function (NF) integration - integrated with multiple third-party vendors, including 4G and 5G access networks (eNodeBs and gNodeBs) and subscriber and policy management functions.
- Converged architecture : Supports 2G, 3G, 4G, 5G non-standalone (NSA), and 5G standalone (SA) modes and enables all access technologies to run on a common cloud-native platform provided by Deutsche Telekom.
Ashok Khuntia, President for Core Networks at Mavenir, said, “Working with Mobile Network Operators globally, we’ve created an agile software delivery process that accommodates specific integration and feature requirements. Integrating Mavenir’s Converged Packet Core into Magyar Telekom’s existing network will enable a fully automated network with the reliability, scale and flexibility to deliver innovative services. Mavenir is pleased to continue to expand our relationship across the Deutsche Telekom subsidiary accounts in Europe.”
About Magyar Telekom:
Magyar Telekom is Hungary’s largest telecommunication operator, it was established in 1991. It provides a full range of telecommunications and infocommunications (ICT) services including fixed line and mobile telephony, data transmission and non-voice as well as IT and systems integration services. Magyar Telekom is the majority owner of Makedonski Telekom, the leading fixed line and mobile operator in the Republic of North Macedonia. Magyar Telekom’s majority shareholder (61.39%) is Deutsche Telekom Europe B.V., fully owned by Deutsche Telekom AG. www.telekom.hu
About Mavenir:
Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision of a single, software-based automated network that runs on any cloud. As the industry's only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, accelerating software network transformation for 250+ Communications Service Providers and Enterprises in over 120 countries, which serve more than 50% of the world’s subscribers. www.mavenir.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221115005128/en/
Contact information
Magyar Telekom PR Contact:
sajto@telekom.hu
Mavenir PR Contact:
PR@mavenir.com
Maryvonne Tubb (US)
Emmanuela Spiteri (EMEA)
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NTT DOCOMO BUSINESS and Chile’s State-owned Copper Company CODELCO Launch a Study and Proof of Concept Aimed at Improving the Efficiency of Remote Copper Mine Operations Using IOWN ® APN6.8.2026 07:30:00 EEST | Press release
NTT DOCOMO BUSINESS, Inc. (formerly NTT Communications Corporation) has launched a study and proof of concept jointly with Corporación Nacional del Cobre de Chile (CODELCO) to progress remote operations at CODELCO’s copper mines using an IOWN® All-Photonics Network (APN).1 This initiative is part of a research project commissioned by Japan’s Ministry of Internal Affairs and Communications.2 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806845222/en/ Conceptual Diagram of the Demonstration To address operational challenges faced by CODELCO’s copper mines, the initiative will connect a copper mine and a remote operations center—approximately 1,500 km apart—via an IOWN APN. It will assess the feasibility of remotely operating heavy machinery using high-capacity, low-latency communication links, enhancing monitoring operations through high-definition video, and implementing a remote operations model. 1. Background Chile is o
FPT Named an OpenAI Select Partner6.8.2026 03:00:00 EEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 01:10:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of ORZEYFUL marks a new chapter for the narcolepsy type 1 community, as we introduce an entirely new class of medicine that will potentially redefine how this disease is managed and howpeople feel on treatment,” said Julie Kim, president and chief executive officer of Takeda. “We are proud to have discovered and developed this orexin treatment innovation and will bring it to adults living with NT1 as quickly as possible.” NT1 is a rare, chronic neurological disease d
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 23:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 17:05:00 EEST | Press release
Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership, and operational excellence with a track record of execution from first-in-human studies through regulatory
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom